摘要
目的:观察吡格列酮对2型糖尿病患者c反应蛋白(CRP)和胰岛素敏感性的影响。方法:103例2型糖尿病患者分为A、B 2组,均给予常规降糖药物治疗,A组每天增加30 mg的吡格列酮片口服。2组均观察24周,治疗前后检查CRP、血糖(FBG)、胰岛素(FINS)、血脂和肝功能,测量血压、身高和体重。结果:①与治疗前比较,A组CRP、胰岛素抵抗指数(HOMA-IR)、血生化、胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白胆固醇(LDL-C)均明显降低(P<0.05),高密度脂蛋白胆固醇(HDL-C)轻度升高(P<0.05),B组各项指标均无明显变化。②CRP与HOMA-IR、BMI、FBG、TC、TG、LDL-C、收缩压和舒张压呈正相关,与HDL-C呈负相关。结论:2型糖尿病患者存在低度炎症状态,吡格列酮在改善HOMA-IR及其相关代谢指标的同时,可降低CRP。
Objective：To observe the effects of pioglitazone on serum C-reaction protein （CRP） and insulin sensitivity in the type 2 DM patients. Methods： 103 cases of type 2 DM patients were divided into pioglitazone group and control group. Fasting serum CRP, Homa-IR, FBG, blood lipid and liver function were determined, and blood pressure, body height and body weight were recorded before and after treatment. Results： （1） Compared with basal values, CRP, HomaIR, systolic pressure, diastolic pressure, TC, TG and LDL-C in pioglitazone group were decreased significantly （P〈0.05）, but HDL-C increased slightly （P〈0.05） after 24 weeks; （2） CRP had a positive relationship with Homa-IR, BMI, TC, TG, LDL- C, systolic pressure and diastolic pressure and a negative relationship with HDL-C. Conclusion： Type 2 DM patients have mild inflammatory state. Pioglitazone can improve insulin resistance and related metabolic disturbance, and simultaneously reduce CRP.
出处
《中国康复》
2006年第2期105-106,共2页
Chinese Journal of Rehabilitation
关键词
吡格列酮
糖尿病
C反应蛋白
胰岛素
pioglitazone
diabetes mellitus
C-reaction protein
insulin
